FOSTAMATINIB

Search structure
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: Parent Prodrug
ATC: B02BX09
UNII: SQ8A3S5101

Structure
InChI Key GKDRMWXFWHEQQT-UHFFFAOYSA-N
Smile COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC
InChI
InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H26FN6O9P
Molecular Weight 580.47
AlogP 3.09
Hydrogen Bond Acceptor 12.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 10.0
Polar Surface Area 186.72
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 40.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Tyrosine-protein kinase SYK inhibitor PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Syk family
- 17-12000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Purpura, Thrombocytopenic, Idiopathic 3 D016553 ClinicalTrials
Arthritis, Rheumatoid 3 D001172 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Glomerulonephritis, IGA 2 D005922 ClinicalTrials
Anemia, Hemolytic, Autoimmune 2 D000744 ClinicalTrials
Primary Myelofibrosis 2 D055728 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Ovarian Neoplasms 1 D010051 ClinicalTrials
Pneumonia 1 D011014 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials

Related Entries

Scaffolds

Salt

Cross References

Resources Reference
CAS NUMBER 901119-35-5
ChEMBL CHEMBL2103830
DrugBank DB12010
DrugCentral 5280
FDA SRS SQ8A3S5101
Guide to Pharmacology 7796
PDB 2RC
PubChem 11671467
SureChEMBL SCHEMBL1201371
ZINC ZINC000043131420
CONTENTS